Opportunistic screening for atrial fibrillation (AF) is recommended for all patients aged over 65 years, and choosing between a rate and rhythm control strategy is important. Beta-blockers or nondihydropyridine calcium
channel antagonists are the first choice for rate control.
Flecainide is preferable for the pharmacologic rhythm control. The sexless CHA2DS2-VA assessment is recommended to assess stroke risk. Integrated care to support comprehensive treatment and address the specific needs of people with AF is required, and GPs are central to its effective delivery.
Modern Medicine – Issue 4 2020